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Background
Protective effects of NO, a physiological activator of solu-
ble guanylyl cyclase (sGC), have been reported in
ischemia/reperfusion syndrome (I/R) of the lung. How-
ever, its protective effects can be overwhelmed by its dele-
terious effects due to oxidative products formation.
Therefore, we studied the effects of direct sGC stimulator
(BAY 41-2272) and sGC activator (BAY 58-2667) on I/R
injury of the lung in a isolated intact organ model.
Materials and methods
Lung injury was assessed by measurements of weight gain
and microvascular permeability (capillary filtration coef-
ficient (Kfc)). Production of reactive oxygen species (ROS)
in tissue and release into the perfusate were measured dur-
ing early reperfusion by ESR spectroscopy. BAY 41-2272,
BAY 58-2667, or apocynin were applied 5 min before
ischemia according to the protocol. NO was admixed into
the inspiration loop of the ventilator at a dose of 20 ppm
1 min before reperfusion.
Results
In untreated lungs dramatic rise in Kfc values and weight
gain during reperfusion were observed. This was associ-
ated with increased ROS production. NO, BAY 41-2272,
and BAY 58-2667 significantly attenuated vascular leak-
age and suppressed ROS release. In an additional set of
experiments BAY 41-2272 diminished PMA induced ROS
production by NADPH-oxidases. Involvement of ROS
generated by NADPH-oxidases in I/R was demonstrated
by favorable effects of enzyme inhibition by apocynin.
Moreover, NADPH oxidase activity, as measured in the
membrane fractions from lung homogenates, was
reduced in the BAY 41-2272 treatment group. NO pro-
tected against vascular leakage, however with less promi-
nent effects as compared to sGC activator and stimulator.
Conclusion
Thus, sGC stimulator and activator protect against I/R
induced lung injury. Partly, this effect can be explained by
prevention of NADPH oxidase activation. sGC stimula-
tors and activators demonstrated better protection against
I/R induced lung injury compared to inhalative NO.
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